DRG Epidemiology's coverage of type 1 diabetes comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed incidence and diagnosed prevalence of type 1 diabetes for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

DRG Epidemiology's type 1 diabetes forecast will answer the following questions:

  • Of all people with type 1 diabetes, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of type 1 diabetes over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following type 1 diabetes patient populations:

  • Diagnosed prevalent cases.
  • Diagnosed prevalent cases by drug treatment.
  • Diagnosed incident cases.
  • Lifetime DALYs gained.

Note: Coverage may vary by country and region.

Table of contents

  • Type 1 Diabetes - Epidemiology - Epidemiology Dashboard

Author(s): Joseph Granato, MPH; Nicole Zhang, MPH

Joseph Granato joined Decision Resources Group in 2012 and previously worked on both Market Access and Global Market Access products.  Joseph is currently responsible for forecasting the prevalence and incidence of disease populations throughout the world.  He is also tasked with identifying at risk populations and developing new epidemiological methods used to predict overall population health.

He received his M.P.H. from Des Moines University where he worked on several population health projects including the delivery of continuing medical education on tick-borne diseases.  He also holds a B.S. in Animal Science from the University of Tennessee.  Prior to his time with DRG Joseph worked with the Monroe County Health Department on the surveillance of reportable diseases including Dengue Fever.

Nicole Zhang is an Epidemiologist at Decision Resources Group. She focuses on the epidemiology of oncology and cardiovascular disorders.

She holds an M.P.H. from Tufts Medical School where she specialized in epidemiology and biostatistics. She also holds a B.A. in Chemistry and Statistics from Mount Holyoke College. Prior to joining Decision Resources, she worked as a research analyst at Massachusetts General Hospital where she independently managed data from food information survey conducted in Chelsea, MA. She has also worked at Massachusetts Department of Public Health where she conducted secondary research in the fields of gestational diabetes.


Related Reports

Bladder Cancer - Landscape & Forecast - Disease Landscape & Forecast

The 2016/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the treatment landscape for advanced bladder cancer, which has historically b...

View Details

Type 1 Diabetes - Landscape & Forecast - Disease Landscape & Forecast

The number of treatment options continues to increase in the T1D space. Existing agents fail to provide sustained and intrinsic control of

View Details

Type 1 Diabetes - Epidemiology - Mature Markets

DRG Epidemiology's coverage of type 1 diabetes comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of type 1 di...

View Details

Type 1 Diabetes - Epidemiology - Asia-Pacific Data

DRG Epidemiology's coverage of type 1 diabetes comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and diagnosed pre...

View Details